Author

John P. Miller

University of RochesterPrimary ORCID profile (0000-0002-3405-2576 · 2 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

John P. MilleriD2 papers · Health Canada

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Cameron D. BakeriD· 1 shared Cameron W. A. SnyderiD· 1 shared Charles C. ChuiD· 1 shared Elizabeth Lamere· 1 shared Elizabeth Pritchett· 1 shared Jeevisha BajajiD· 1 shared John M. AshtoniD· 1 shared Kyukwang KimiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Cameron D. BakerORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

IL-1β/IRAK4 Axis Promotes Ovarian Tumor Development at the Mesothelium Injury Sites

John P. Miller, Kyukwang Kim, Negar Khazan, Cameron W. A. Snyder, Niloy A. Singh, Elizabeth Lamere, Myla S. Strawderman, Sonali Sharma, Ronald Lakony, Michelle Whittum, Mark Anderson, Rick Keenan, Elizabeth Pritchett, Cameron D. Baker, John M. Ashton, , Rakesh K. Singh

This paper develops a MIM model to study EOC metastasis at mesothelial injury sites and shows IRAK4 inhibitors reduce tumor burden more effectively than IL-1/IL-1R1 targeting agents.

bioRxiv · Mar 18, 2025 · PreprintCancer Biology